Mutations in proteins essential for HR, such as the breast cancer early onset (BRCA1 & BRCA2) tumor suppressor genes, have been associated with increased risk of tumor development and enhanced sensitivity to chemotherapeutic agents [3, 4, 5, 6, 7]. Here, BRCA2 is linked to neoplasm.